Breakthrough pancreatic cancer drug sparks huge patient demand at US clinics

US cancer centers are grappling with an influx of patient requests for an experimental pancreatic cancer drug, daraxonrasib, as they navigate an early access program while awaiting what many hope will be swift Food and Drug Administration (FDA) approval. The FDA gave the green light to the…